AR and neoplasm: However, the resistance to the PARP inhibitor, the lack of the androgen receptor (45–88% in TNBC) [42], or the rare expression of PD‐L1 in noninflamed tumor cells [43] all dampen the therapeutic efficacy and limit the application of those approaches in TNBC.